Merck & Co., Inc. (MRK) yesterday, won the US Food and Drug Administration’s (FDA) Accelerated Approval for its breakthrough cancer therapy, Keytruda. It beat Bristol-Myers Squibb Co. (BMY) by becoming the first company first to get approval for a PD-1 inhibitor drug in the US. Keytruda has been approved for the treatment of advanced melanoma in patients who have failed treatments with Bristol-Myers’ Yervoy and other drugs.
Eli Lilly and Co (NYSE:LLY) announced two separate collaborations, one with Merck & Co., Inc. (NSYE:MRK), and the other with Bristol-Myers Squibb Co (NYSE:BMY), to conduct the clinical tests of cancer drugs developed by both companies.
By Peter Geschek:Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance.A new wave of immunotherapy drugs, in the spotlight of the upcoming ASCO (American Society of Clinical Oncology) meeting, promises to produce longer-lasting remissions.
Bristol-Myers Squibb Co (NYSE:BMY) and Merck & Co., Inc.’s (NYSE:MRK) respective cancer immunotherapies, Opdivo and Keytruda, showed promising results for the treatment of Hodgkin’s lymphoma in two separate studies, researchers announced Saturday.
Eli Lilly and Co (LLY) announced positive results from Phase III RAISE trials on CYRAMZA (Ramucirumab) yesterday, which will be used to treat metastatic Colorectal Cancer (mCRC), in combination with chemotherapy.
Agios Pharmaceuticals Inc (NASDAQ:AGIO) was up 8.21% in extending trading yesterday after it announced positive preliminary data from Phase-I trials of its first-in-class oncology therapy, AG-120. The drug showed clinical activity and human safety against hematologic malignancies, including acute myeloid leukemia (AML) in patients with IDH1 mutation.